Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients
Carregando...
Citações na Scopus
71
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
BATISTA JR., Miguel L.
HENRIQUES, Felipe S.
NEVES, Rodrigo X.
OLIVAN, Mireia R.
MATOS-NETO, Emidio M.
ALVES, Michele J.
SEELAENDER, Marilia
Citação
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, v.7, n.1, p.37-47, 2016
Resumo
Background and aimsCachexia is a syndrome characterized by marked involuntary loss of body weight. Recently, adipose tissue (AT) wasting has been shown to occur before the appearance of other classical cachexia markers. We investigated the composition and rearrangement of the extracellular matrix, adipocyte morphology and inflammation in the subcutaneous AT (scAT) pad of gastrointestinal cancer patients. MethodsSurgical biopsies for scAT were obtained from gastrointestinal cancer patients, who were signed up into the following groups: cancer cachexia (CC, n=11), weight-stable cancer (WSC, n=9) and weight-stable control (non-cancer) (control, n=7). The stable weight groups were considered as those with no important weight change during the last year and body mass index <25kg/m(2). Subcutaneous AT fibrosis was quantified and characterized by quantitative PCR, histological analysis and immunohistochemistry. ResultsThe degree of fibrosis and the distribution and collagen types (I and III) were different in WSC and CC patients. CC patients showed more pronounced fibrosis in comparison with WSC. Infiltrating macrophages surrounding adipocytes and CD3 Ly were found in the fibrotic areas of scAT. Subcutaneous AT fibrotic areas demonstrated increased monocyte chemotactic protein 1 (MCP-1) and Cluster of Differentiation (CD)68 gene expression in cancer patients. ConclusionsOur data indicate architectural modification consisting of fibrosis and inflammatory cell infiltration in scAT as induced by cachexia in gastrointestinal cancer patients. The latter was characterized by the presence of macrophages and lymphocytes, more evident in the fibrotic areas. In addition, increased MCP-1 and CD68 gene expression in scAT from cancer patients may indicate an important role of these markers in the early phases of cancer.
Palavras-chave
Adipose tissue, Extracellular matrix, Fibrosis, Inflammation, Cachexia
Referências
- Pond CM, 2005, PROSTAG LEUKOTR ESS, V73, P17, DOI 10.1016/j.plefa.2005.04.005
- Skurk T, 2007, J CLIN ENDOCR METAB, V92, P1023, DOI 10.1210/jc.2006-1055
- Kolehmainen M, 2008, INT J OBESITY, V32, P292, DOI 10.1038/sj.ijo.0803718
- Arner P, 2011, SCIENCE, V333, P163, DOI 10.1126/science.1209418
- Batista ML, 2012, CYTOKINE, V57, P9, DOI 10.1016/j.cyto.2011.10.008
- Tsoli M, 2013, TRENDS ENDOCRIN MET, V24, P174, DOI 10.1016/j.tem.2012.10.006
- Fearon K, 2013, NAT REV CLIN ONCOL, V10, P90, DOI 10.1038/nrclinonc.2012.209
- Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrg927
- Bing C, 2008, CURR OPIN CLIN NUTR, V11, P201, DOI 10.1097/MCO.0b013e3282f948e2
- Elgazar-Carmon V, 2008, J LIPID RES, V49, P1894, DOI 10.1194/jlr.M800132-JLR200
- Ryden M, 2013, J LIPID RES, V54, P2909, DOI 10.1194/jlr.M040345
- Fearon K, 2011, LANCET ONCOL, V12, P489, DOI [10.1016/S1470-2045(10)70218-7, 10.1016/51470-2045(10)70218-7]
- Argiles JM, 2012, DRUG DISCOV TODAY, V17, P702, DOI 10.1016/j.drudis.2012.02.001
- Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994
- Argiles JM, 2010, J AM MED DIR ASSOC, V11, P229, DOI 10.1016/j.jamda.2010.02.004
- Bohle A, 1998, NEPHROL DIAL TRANSPL, V13, P556, DOI 10.1093/ndt/13.3.556
- Machado AP, 2004, CELL TISSUE RES, V318, P503, DOI 10.1007/s00441-004-0987-2
- Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077
- Das SK, 2013, TRENDS MOL MED, V19, P292, DOI 10.1016/j.molmed.2013.02.006
- Arner P, 2007, J INTERN MED, V262, P404, DOI 10.1111/j.1365-2796.2007.01850.x
- Bertevello PS, 2001, BRAZ J MED BIOL RES, V34, P1161, DOI 10.1590/S0100-879X2001000900009
- Khan T, 2009, MOL CELL BIOL, V29, P1575, DOI 10.1128/MCB.01300-08
- Ryden M, 2008, CANCER, V113, P1695, DOI 10.1002/cncr.23802
- Agustsson T, 2007, CANCER RES, V67, P5531, DOI 10.1158/0008-5472.CAN-06-4585
- Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973
- Seelaender M, 2012, CLIN NUTR, V31, P562, DOI 10.1016/j.clnu.2012.01.011
- Divoux A, 2010, DIABETES, V59, P2817, DOI 10.2337/db10-0585
- Dodson S, 2011, ANNU REV MED, V62, P265, DOI 10.1146/annurev-med-061509-131248
- Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
- Fearon KC, 2006, AM J CLIN NUTR, V83, P1345
- Dahlman I, 2010, PROG MOL BIOL TRANSL, V94, P39, DOI 10.1016/S1877-1173(10)94003-9
- Ciangura C, 2010, OBESITY, V18, P760, DOI 10.1038/oby.2009.348
- Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487
- Pierleoni C, 1998, EUR J HISTOCHEM, V42, P183
- Batista ML, 2013, CYTOKINE, V61, P532, DOI 10.1016/j.cyto.2012.10.023
- Kemik O, 2012, HUM EXP TOXICOL, V31, P117, DOI 10.1177/0960327111417271
- Hotamisligil GS, 2008, INT J OBESITY, V32, pS52, DOI 10.1038/ijo.2008.238
- Petruzzelli M, 2014, CELL METAB, V20, P433, DOI 10.1016/j.cmet.2014.06.011
- Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008
- Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887
- Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013
- Batista ML, 2012, J ENDOCRINOL, V215, P363, DOI 10.1530/JOE-12-0307
- Beluzi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122660
- Bing C, 2006, BRIT J CANCER, V95, P1028, DOI 10.1038/sj.sjc.6603360
- Bing Chen, 2011, Curr Opin Support Palliat Care, V5, P356, DOI 10.1097/SPC.0b013e32834bde0e
- CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
- Henegar C, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r14
- Kwon Sung Joon, 2011, J Gastric Cancer, V11, P78, DOI 10.5230/jgc.2011.11.2.78
- Moraes-Vieira PM, 2014, CELL METAB, V19, P512, DOI 10.1016/j.cmet.2014.01.018
- Mutch DM, 2009, AM J CLIN NUTR, V89, P51, DOI 10.3945/ajcn.2008.26802
- vansEijk M, 2009, PLOS ONE, V4, pe4723